Screening of the recurrently mutated genes. (A) Percentage of FR-CLL primary cases harboring mutations in candidate genes after targeted resequencing of a screening dataset (total N = 58 FR-CLL, including discovery and screening cases). The number of mutated cases over total analyzed is as follows: TP53, 16/58 (27.6%); NOTCH1 14/58 (24.1%); SF3B1 11/58 (18.9%); FAT1 6/58 (10.3%); UTRN 2/58 (3.4%); TSC1 2/58 (3.4%); FPGT 2/58 (3.4%). (B) Prevalence of TP53 (P = .002), NOTCH1 (P = .057), SF3B1 (P = .012), and FAT1 (P = .004) mutations in 58 FR-CLL vs 174 unselected CLL cases at diagnosis.